Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi : $621.13 Million Federal Contract Awarded to Sanofi Pasteur

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/12/2019 | 02:42am EDT

ATLANTA, Georgia, Jan. 11 -- Sanofi Pasteur Inc., Swiftwater, Pennsylvania, won a $621,134,986 federal contract from the U.S. Department of Health and Human Services' Centers for Disease Control and Prevention for pediatric influenza vaccines.

Agency contacts: Monica D. Shaw, 770/488-8213, monica.shaw@cdc.hhs.gov; or Pellumbeshe Hoxhaj, 770/488-2805, kfx2@cdc.gov. CIV5FCA5. CLASS65; NAICS325412.

For more information about Targeted News Service's products, including its daily federal contract report, please contact: Myron Struck, Myron@targetednews.com, Editor, Targeted News Service LLC, Springfield, Va., Direct: 703/866-4708, Cell: 703/304-1897.

© 2019 Targeted News Service, source News Service

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
04:37pGilead invests $5 billion to deepen ties with biotech Galapagos
RE
04:27pGilead invests $5 billion to deepen ties with biotech Galapagos
RE
03:26aSANOFI : Press releases
PU
07/10SANOFI : FDA to Review Isatuximab for Relapsed/Refractory Multiple Myeloma
DJ
07/10SANOFI : Press releases
PU
07/10SANOFI : FDA to review isatuximab as a potential treatment for relapsed/refracto..
GL
07/09Drugmakers Rise After Trump Pricing Rule Is Blocked
DJ
07/09SWEDISH ORPHAN BIOVITRUM : Switching to extended half-life prophylaxis impacted ..
AQ
07/08SANOFI : Swedish Orphan Biovitrum AB - Interim data evaluating Elocta for Immune..
AQ
07/08SWEDISH ORPHAN BIOVITRUM : Interim data evaluating Elocta® for Immune Tolerance ..
AQ
More news
Financials (EUR)
Sales 2019 35 944 M
EBIT 2019 9 387 M
Net income 2019 4 931 M
Debt 2019 14 981 M
Yield 2019 4,24%
P/E ratio 2019 19,0x
P/E ratio 2020 16,2x
EV / Sales2019 2,98x
EV / Sales2020 2,79x
Capitalization 92 223 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 86,7  €
Last Close Price 73,8  €
Spread / Highest target 35,5%
Spread / Average Target 17,5%
Spread / Lowest Target 7,06%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-2.85%105 687
JOHNSON & JOHNSON4.07%372 000
PFIZER-2.86%238 617
ROCHE HOLDING LTD.7.93%233 930
ROCHE HOLDING9.69%233 930
MERCK AND COMPANY4.35%208 546